Singapore, Sept. 4 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Randomized, Double-Blind, Placebo-controlled, Multicenter, Parallel-group Study to Eval... Read More
Singapore, Sept. 4 -- The Health Sciences Authority received information related to the study titled 'Responses Against Paramyxoviruses in T cells with crOss Reactivity'. The following are the other r... Read More
Singapore, Sept. 4 -- The Health Sciences Authority received information related to the study titled 'Effect of innate immune reprogramming by primary dengue on host response to secondary dengue'. The... Read More
Singapore, Sept. 4 -- The Health Sciences Authority received information related to the study titled 'Validation of Gore Test in patients with Sphincteric Dyssynergia presenting with Dysfunctional Voi... Read More
Singapore, Sept. 4 -- The Health Sciences Authority received information related to the study titled 'An open-label, randomized, controlled phase 3 study of enfortumab vedotin in combination with pemb... Read More
Singapore, Sept. 4 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study to Investigate the Safety and... Read More
Singapore, Sept. 4 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study to Investigate the Safety and... Read More
Singapore, Sept. 4 -- The Health Sciences Authority received information related to the study titled 'A double-blind, randomised, placebo-controlled trial evaluating the efficacy and safety of oral ne... Read More
Singapore, Sept. 4 -- The Health Sciences Authority received information related to the study titled 'A Phase 1, Randomized, Placebo-Controlled, Investigator and Participant Blinded, Single Ascending ... Read More
Singapore, Sept. 4 -- The Health Sciences Authority received information related to the study titled 'A Randomized, Double-Blind, Active-Control, Multicenter Phase 3 Trial of Casdatifan and Cabozantin... Read More